Else Marit Inderberg

19PUBLICATIONS
47CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersTumour immunologyMedical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Feb 25, 2025
Generation of frameshift-mutated TGFβR2-specific T cells in healthy subjects following administration with cancer vaccine candidate FMPV-1/GM-CSF in a phase 1 study.

Else Marit Inderberg, Nand Singh, Robert Miller

|Jun 07, 2024
CD20 expression regulates CD37 levels in B-cell lymphoma - implications for immunotherapies.

Malgorzata Bobrowicz, Aleksandra Kusowska, Marta Krawczyk

|May 10, 2023
T cell receptor repertoire sequencing reveals chemotherapy-driven clonal expansion in colorectal liver metastases.

Eirik Høye, Vegar J Dagenborg, Annette Torgunrud

|Jan 30, 2023
Impact of human telomerase reverse transcriptase peptide vaccine combined with androgen deprivation therapy and radiotherapy in de novo metastatic prostate cancer: Long-term clinical monitoring.

Wolfgang Lilleby, Therese Seierstad, Else Marit Inderberg

|Apr 23, 2022
Emerging Biomarkers for Immunotherapy in Glioblastoma.

Nadia Mensali, Else Marit Inderberg

|Nov 11, 2021
Long-term first-in-man Phase I/II study of an adjuvant dendritic cell vaccine in patients with high-risk prostate cancer after radical prostatectomy.

Anne M A Tryggestad, Karol Axcrona, Ulrika Axcrona

Pageof 4

Frequent Collaborators

10 joint publications

Sébastien Wälchli

5 joint publications

Pierre Dillard

5 joint publications

Nadia Mensali

4 joint publications

Gustav Gaudernack